Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHM 1101

Next Previous
X
Search
Drug Profile

CHM 1101

Alternative Names: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes; Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes - City of Hope National Medical Center; chlorotoxin chimeric antigen receptor (CLTX-CAR) T cell therapy - City of Hope National Medical Center; Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells; Chlorotoxin-CD28-CD3z-CD19t-expressing-CAR-T-cells-Chimeric Therapeutics/City-of-Hope-National-Medical-Center; CHM-1101

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Chimeric Therapeutics; City of Hope National Medical Center
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; Peptides
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical Colorectal cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 11 Dec 2023 Preclinical trials in Solid tumours in Australia (Parenteral), prior to December 2023 (Chimeric therapeutics pipeline, December 2023)
  • 04 Jun 2023 CHM 1101 is still in phase I development for Glioblastoma (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (Intraventricular, Injection) ( NCT04214392)
  • 04 Jun 2023 CHM 1101 is still in phase I development in Glioblastoma (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT04214392)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top